Abstract
The primary objectives of this large multicenter study (n = 578) were to determine the efficacy and safety of moclobemide, 300 or 600 mg per day, for the treatment of social phobia. A double-blind fixed-dose parallel group study was conducted to compare the two different doses of moclobemide to placebo. After a 1-week placebo run-in period, patients were randomly assigned to one of the three treatment groups to receive the test compound for a 12-week period. Assessments were performed at screen, on baseline and on weeks 1, 2, 3, 4, 6, 8, 10, and 12. There were consistent, reliable and clinically meaningful drug effects and indications of a dose-response relationship. Statistical analysis of the results at both weeks 8 and 12 showed that 600 mg of moclobemide was effective and statistically significantly superior to placebo. The 300 mg dose also showed better efficacy than placebo on all measures of efficacy, and about half of them were statistically significantly different from placebo. Moclobemide was well tolerated. Adverse events, except for insomnia, were neither dose-related nor were there significant drug-placebo differences. The results indicate that 600 mg of moclobemide per day given b.i.d. is effective in social phobia, reducing the symptoms and the impairment associated with the disorder. The compound is well tolerated and safe.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). American Psychiatric Association, Washington DC
Amies PL, Gelder MG, Shaw PM (1983) Social phobia: a comparative clinical study. Br J Psychiatry 142:174–179
Bisserbe J-C, Lépine J-P, GRP Group (1994) Moclobemide in social phobia: a pilot open study. Clin Neuropharmacol 17:88–94
Davidson JRT, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH (1993a) Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 13:423–428
Davidson JRT, Hughes DL, George LK, Blazer DG (1993b) The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol Med 23: 709–718
Fahlén T, Humble M, Koczkas C, Nilsson HL (1992) Social phobia and its treatment with brofaromine. Efficacy regarding social phobia symptoms and personality traits. Clin Neuropharmacol 15:64B
First M, Spitzer RL, Williams JBW, Gibbon M (1995) Structured Clinical Interview for DSM-IV — Patient Edition (SCIP-P). American Psychiatric Press, Washington DC
Gelemter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ (1991) Cognitive-behavioral and pharmacological treatments of social phobia. Arch Gen Psychiatry 48:938–945
Gelemter CS, Stein MB, Tancer ME, Uhde TW (1992) An examination of syndromal validity and diagnostic subtypes in social phobia and panic disorder. J Clin Psychiatry 53:23–27
Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C (1995) Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52:289–295
Guy W (1976) Early Clinical Drug Evaluation Unit (ECDEU) assessment manual. US Department of Health, Education and Welfare, Washington DC, pp 217–222
Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55
Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC (1995) Sertraline in social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 152: 1368–1371
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51:8–19
Liebowitz MR, Gorman JM, Fyer AJ, Klein DF (1985) Social phobia: review of a neglected anxiety disorder. Arch Gen Psychiatry 42:729–736
Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, Levin A (1986) Phenelzine in social phobia. J Clin Psychopharmacol 6:93–98
Liebowitz MR (1987) Social phobia. Modem problems in pharmacopsychiatry 22:141–173
Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AP, Sandberg D, Hollander E, Papp L, Goetz D (1988) Pharmacotherapy of social phobia: an interim report of a placebo controlled comparison of phenelzine and atenolol. J Clin Psychiatry 49:252–257
Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, Klein DF (1992) Phenelzine vs atenolol in social phobia: a placebo controlled comparison. Arch Gen Psychiatry 49:290–300
Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC (1996) Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 53: 159–168
Manuzza S, Schneier FR, Chapman TF, Liebowitz MR, Klein DF, Fyer AJ (1995) Generalized social phobia: reliability and validity. Reference for social phobia subtype. Arch Gen Psychiatry 52:230–237
Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389
Myers JK, Weissman MM, Tischler GL, Holzer CE, Leaf PJ, Orvaschel H, Anthony JL, Boyd JH, Burke JD, Kramer M, Stoltzman R (1984) Six month prevalence of psychiatric disorders in three countries. Arch Gen Psychiatry 41:959–967
Schneier FR, Johnson J, Homig CD, Liebowitz MR, Weissman MM (1992) Social phobia. Comorbidity and morbidity in an epidemiological sample. Arch Gen Psychiatry 49:282–288
Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, Street L, Del Bene D, Liebowitz MR (1993) Functional impairment in social phobia. J Clin Psychiatry 55:322–331
Sheehan DV (1983) The anxiety disease and how to overcome it. Schribner, New York, pp 148–149
Solyom L, Ledwidge B, Solyom C (1986) Delineating social phobia. Br J Psychiatry 149: 464–470
Spitzer RL, Williams JBW, Gibbon M, First M (1990) Structured Clinical Interview for DSM-III-R — Patient Edition (SCIP-P). American Psychiatric Press, Washington DC
Stahl M, Biziere K, Schmid-Burgk W, Amrein R (1989) Review of comparative clinical trials: moclobemide vs tricyclic antidepressants and vs placebo in depressive states. J Neural Transm 45:77–90
Stein MB (1996) How shy is too shy? Lancet 347:1131–1132
Swinson RP, Cox BJ, Woszczyna CB (1992) Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. Can Med Assoc J 147:878–883
Van Vliet IM, Boer JA den, Westenberg HGM (1992) Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 2:21–29
Van Vliet IM, Boer JA den, Westenberg HGM (1994) A novel psychopharmacological approach to social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology 115:128–134
Versiani M (1992) Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 161: 353–360
Versiani M, Mundim FD, Nardi AE, Liebowitz MR (1988) Tranylcypromine in social phobia. J Clin Psychopharmacol 8:279–283
Versiani M, Oggero U, Alterwain P, Capponi R, Dajas F, Heinze-Martin G, Marquez CA, Poleo MA, Rivero-Almanzor LE, Rossel L, Schmid-Burgk W, Ucha Udabe R (1989) A doubleblind comparative trial of moclobemide vs imipramine and placebo in major depressive episodes. Br J Psychiatry 155:72–77
World Health Organisation (1992) Mental health and behavioral disorders (including disorders of psychological development). In: International classification of diseases, 10th rev. World Health Organisation, Geneva, Switzerland
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia., Katschnig, H. Moclobemide in social phobia. Eur Arch Psychiatry Clin Nuerosci 247, 71–80 (1997). https://doi.org/10.1007/BF02900196
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02900196